Clinical trials: neoadjuvant therapy
Esophageal Squamous Cell Carcinoma
Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma
Esophageal cancer is one of common malignant tumors in China and esophageal squamous cell carcinoma (ESCC) is the dominant pathological type, accounting for more than 95% of all cases.
- Trial name
- NCT02272699
- Testing
- Nimotuzumab, Paclitaxel, Cisplatin
- Where
- China
- Sponsor
- Peking University
Muscle Invasive Bladder Cancer Urothelial Carcinoma
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Cancer: A Multicenter Study
This is a single-arm, open-label, multicenter clinical trial to investigate the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as perioperative treatment in patients with muscle-invasive bladder…
- Trial name
- NCT05328336
- Testing
- Tislelizumab Nab paclitaxel
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Tianjin Medical University Second Hospital
Glioma
Phase 2 Study of IDH305 in Low Grade Gliomas
Cohort A - neoadjuvant administration of IDH305 at 550 mg BID for 6 weeks followed by surgical resection at 6 weeks. If there is no evidence of progressive disease at 6 weeks (clinical, radiographic or histopathologic exam), the…
- Trial name
- NCT02987010
- Testing
- IDH305
- Sponsor
- University of Texas Southwestern Medical Center
Early Stage Breast Carcinoma
Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy
Radiation therapy after surgery to remove breast cancer improves control of the breast cancer. Standard therapy after breast conservation surgery is five to six weeks of radiation to the entire breast.
- Trial name
- SIGNAL 2 (NCT02212860)
- Testing
- Stereotactic Body Radiation Then Surgery
- Where
- Canada
- Volunteers
- 139 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Cutaneous Squamous Cell Carcinoma, Skin Cancer
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
The purpose of the study is to see if the combination of radiation therapy and cemiplimab immunotherapy is an effective treatment for people with locally advanced, unresectable CSCC.
- Conditions
- Cutaneous Squamous Cell Carcinoma, Skin Cancer, Squamous Cell Carcinoma, Locally Advanced Squamous Cell Carcinoma
- Trial name
- NCT05574101
- Testing
- Cemiplimab, Radiotherapy
- Where
- 13 sites in United States
- Volunteers
- 34 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
The purpose of this study is to assess whether the addition of the immune checkpoint inhibitor Nivolumab to induction chemotherapy will increase the percentage of patients with a complete response on MRI and PET after 3 cycles of…
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharyngeal Neoplasms, Nasopharynx Cancer
- Trial name
- NPC-Nivo (NCT06019130)
- Testing
- Nivolumab, Cisplatin, 5-Fluorouracil
- Where
- 31 sites in Germany
- Volunteers
- 57 people
- Sponsor
- German Society for Pediatric Oncology and Hematology GPOH gGmbH
Breast Cancer, Triple-negative Breast Cancer
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
TNBC is a heterogeneous disease with distinct pathological, genetic, and clinical features among subtypes. Treatment results for high-risk primary TNBC remain poor compared to other breast cancer subtypes.
- Trial name
- ADAPT-TN-IV (NCT07178730)
- Testing
- Sacituzumab govitecan, Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA], SoC Chemotherapy
- Where
- 26 sites in Germany
- Volunteers
- 765 people
- Sponsor
- Women's Cancer Study Group GmbH
Rectal Cancer, Adenocarcinoma, Neoadjuvant Chemoradiation
Multicenter, Prospective, RCT：Investigation of Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.
At present, the combined modality treatment of preoperative neoadjuvant chemoradiotherapy (NCRT) followed by radical surgery has become the standard of care for the locally advanced mid/low rectal cancer, having been proved to…
- Trial name
- NCT03042000
- Testing
- non-NCRT, NCRT, capecitabine with oxaliplatin
- Volunteers
- 1,200 people
- Sponsor
- Peking Union Medical College Hospital
Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC
This study is being done to compare a special type of Positron Emission Tomography (PET) scan with CT scan in patients with surgically removable lung cancer to see which method is more useful in measuring a response to treatment.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma
- Trial name
- NCT00963807
- Testing
- Cisplatin, CT, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer
Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer
The addition of durvalumab to total neoadjuvant therapy (TNT) in locally advanced rectal cancer may improve the pathological complete response rate.
- Trial name
- DUREC (NCT04293419)
- Testing
- Durvalumab (MEDI4736)
- Where
- 10 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Rectal Neoplasms
CONVERT: Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients
Although neoadjuvant radiotherapy greatly decreases local recurrence in locally advanced rectal cancer patients undergoing surgery, it inevitably results in short-term and long-term toxicities.
- Trial name
- NCT02288195
- Testing
- Oxaliplatin, capecitabine, Radiation
- Where
- China
- Volunteers
- 663 people
- Sponsor
- Sun Yat-sen University
Transitional Cell Carcinoma of the Bladder
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
This trial will investigate the activity of sunitinib combined with cisplatin and gemcitabine followed by radical cystectomy in patients with Transitional Cell Carcinoma (TCC) of the Bladder.
- Trial name
- NCT00859339
- Testing
- Gemcitabine, Cisplatin, Sunitinib Malate
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 9 people
- Sponsor
- Noah Hahn, M.D.
Advanced Non-Small Cell Lung Cancer
Study of Participants With Advanced Non-Small Cell Lung Cancer
The purpose of this study is to compare the regimens of pemetrexed, carboplatin with pemetrexed maintenance and paclitaxel, carboplatin, bevacizumab with bevacizumab maintenance in participants with Stage IV nonsquamous non-small…
- Trial name
- NCT00948675
- Testing
- Pemetrexed, Carboplatin, Paclitaxel
- Where
- 45 sites in United States
- Volunteers
- 361 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Photoacoustic Imaging for Characterizing Breast Masses and Breast Tumor Response to Neoadjuvant Chemotherapy
Our objective in this pilot study will be to identify PA parameters that can distinguish benign vs. malignant lesions, and also, if PA parameters change with within breast tumors during chemotherapy treatment over time.
- Trial name
- NCT04428528
- Testing
- Photoacoustics Imaging System
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Sunnybrook Health Sciences Centre
Anaplastic Large Cell Lymphoma, ALK-Positive
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) high-risk ALK+ Anaplastic Large Cell Lymphoma (ALCL) have a low incidence of overall survival.
- Trial name
- ACCELERATE (NCT07013565)
- Testing
- Vinblastine (Velban), Brentuximab vedotin (Adcetris), Nivolumab (Opdivo)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York Medical College
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer
This early phase I trial studies the side effects of durvalumab and tremelimumab before surgery in treating patients with hormone receptor positive, HER2 negative stage II-III breast cancer.
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03132467
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Triple-Negative Breast Cancer (TNBC)
Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC
The goal of this clinical trial is to compare the effectiveness of several treatment regimens for stage I triple negative breast cancer before surgery.
- Trial name
- DETENTE-1 (NCT07786428)
- Testing
- Pembrolizumab, Paclitaxel (Chemotherapy), Carboplatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Rectal Cancer
Lateral Lymph Node Dissection After Neoadjuvant Chemo-radiation in Advanced Low Rectal Cancer
Lateral lymph nodes (LLD) metastasis is a major cause of local recurrence for advanced rectal cancer. As for the treatment strategies on LLN metastasis, there are huge controversies on whether lateral pelvic lymph nodes…
- Trial name
- NCT02614157
- Testing
- LLND, labeled line
- Where
- China
- Volunteers
- 51 people
- Sponsor
- West China Hospital
Invasive Breast Cancer, Inflammatory Breast Cancer Stage III
TRUDI: TDXD+Durva in HER2+/Low IBC
The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor…
- Conditions
- Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma
- Trial name
- TRUDI (NCT05795101)
- Testing
- Trastuzumab deruxtecan, Durvalumab
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- Filipa Lynce, MD
Ulcerative Colitis, Inflammatory Bowel Diseases
Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
The primary objective of this trial is to evaluate the clinical efficacy of ATH-063 in participants with biologic/advanced therapy relapsed/refractory moderately to severely active UC.
- Conditions
- Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases
- Trial name
- Aegean (NCT07513181)
- Testing
- ATH-063
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Athos Therapeutics Inc